Literature DB >> 28215825

Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Andriana G Kotini1, Chan-Jung Chang1, Arthur Chow2, Han Yuan3, Tzu-Chieh Ho2, Tiansu Wang1, Shailee Vora1, Alexander Solovyov4, Chrystel Husser1, Malgorzata Olszewska1, Julie Teruya-Feldstein5, Deepak Perumal6, Virginia M Klimek7, Alexandros Spyridonidis8, Raajit K Rampal7, Lewis Silverman9, E Premkumar Reddy9, Elli Papaemmanuil10, Samir Parekh6, Benjamin D Greenbaum4, Christina S Leslie3, Michael G Kharas11, Eirini P Papapetrou12.   

Abstract

Myeloid malignancy is increasingly viewed as a disease spectrum, comprising hematopoietic disorders that extend across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this study, we derived a collection of induced pluripotent stem cell (iPSC) lines capturing a range of disease stages encompassing preleukemia, low-risk MDS, high-risk MDS, and secondary AML. Upon their differentiation, we found hematopoietic phenotypes of graded severity and/or stage specificity that together delineate a phenotypic roadmap of disease progression culminating in serially transplantable leukemia. We also show that disease stage transitions, both reversal and progression, can be modeled in this system using genetic correction or introduction of mutations via CRISPR/Cas9 and that this iPSC-based approach can be used to uncover disease-stage-specific responses to drugs. Our study therefore provides insight into the cellular events demarcating the initiation and progression of myeloid transformation and a new platform for testing genetic and pharmacological interventions.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute myeloid leukemia; cancer progression; hPSC-derived hematopoiesis; iPSC disease modeling; induced pluripotent stem cells; leukemia; leukemia progression; myelodysplastic syndrome; myeloid malignancy; transplantation

Mesh:

Substances:

Year:  2017        PMID: 28215825      PMCID: PMC5337161          DOI: 10.1016/j.stem.2017.01.009

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  48 in total

1.  Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation.

Authors:  E Flores-Figueroa; G Gutiérrez-Espindola; S Guerrero-Rivera; J Pizzuto-Chavez; H Mayani
Journal:  Leuk Res       Date:  1999-04       Impact factor: 3.156

2.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

3.  Patient-derived induced pluripotent stem cells in cancer research and precision oncology.

Authors:  Eirini P Papapetrou
Journal:  Nat Med       Date:  2016-12-06       Impact factor: 53.440

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

6.  A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies.

Authors:  Elizabeth S Ng; Richard Davis; Edouard G Stanley; Andrew G Elefanty
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 7.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

8.  Distinct routes of lineage development reshape the human blood hierarchy across ontogeny.

Authors:  Faiyaz Notta; Sasan Zandi; Naoya Takayama; Stephanie Dobson; Olga I Gan; Gavin Wilson; Kerstin B Kaufmann; Jessica McLeod; Elisa Laurenti; Cyrille F Dunant; John D McPherson; Lincoln D Stein; Yigal Dror; John E Dick
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

Review 9.  Haematopoietic and immune defects associated with GATA2 mutation.

Authors:  Matthew Collin; Rachel Dickinson; Venetia Bigley
Journal:  Br J Haematol       Date:  2015-02-23       Impact factor: 6.998

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  49 in total

1.  GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.

Authors:  Moonjung Jung; Stefan Cordes; Jizhong Zou; Shiqin J Yu; Xavi Guitart; So Gun Hong; Vinh Dang; Elaine Kang; Flavia S Donaires; Sergio A Hassan; Maher Albitar; Amy P Hsu; Steven M Holland; Dennis D Hickstein; Danielle Townsley; Cynthia E Dunbar; Thomas Winkler
Journal:  Blood Adv       Date:  2018-12-11

Review 2.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

Review 3.  Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids.

Authors:  Ryan C Smith; Viviane Tabar
Journal:  Cell Stem Cell       Date:  2018-12-20       Impact factor: 24.633

4.  From MDS/AML to iPSC and back again.

Authors:  Brian A Jonas
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

5.  Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Authors:  Jia Yi Fong; Luca Pignata; Pierre-Alexis Goy; Kimihito Cojin Kawabata; Stanley Chun-Wei Lee; Cheryl M Koh; Daniele Musiani; Enrico Massignani; Andriana G Kotini; Alex Penson; Cheng Mun Wun; Yudao Shen; Megan Schwarz; Diana Hp Low; Alexander Rialdi; Michelle Ki; Heike Wollmann; Slim Mzoughi; Florence Gay; Christine Thompson; Timothy Hart; Olena Barbash; Genna M Luciani; Magdalena M Szewczyk; Bas J Wouters; Ruud Delwel; Eirini P Papapetrou; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Mark D Minden; Jian Jin; Ari Melnick; Tiziana Bonaldi; Omar Abdel-Wahab; Ernesto Guccione
Journal:  Cancer Cell       Date:  2019-08-12       Impact factor: 31.743

6.  Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.

Authors:  Ruoji Zhou; An Xu; Jian Tu; Mo Liu; Julian A Gingold; Ruiying Zhao; Dung-Fang Lee
Journal:  J Vis Exp       Date:  2018-06-13       Impact factor: 1.355

Review 7.  Modeling Leukemia with Human Induced Pluripotent Stem Cells.

Authors:  Eirini P Papapetrou
Journal:  Cold Spring Harb Perspect Med       Date:  2019-12-02       Impact factor: 6.915

Review 8.  Gene delivery methods and genome editing of human pluripotent stem cells.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Iga Kołodziejczak; Maciej Wiznerowicz
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-18

Review 9.  Cancer in a dish: progress using stem cells as a platform for cancer research.

Authors:  Mo Liu; Jian Tu; Julian A Gingold; Celine Shuet Lin Kong; Dung-Fang Lee
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 10.  Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).

Authors:  Kelly Mitchell; Ulrich Steidl
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.